The association of rheumatoid arthritis and its treatment with sinus disease

Kaleb Michaud, Frederick Wolfe

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective. To determine if rates of sinus disease are increased in patients with rheumatoid arthritis (RA) and whether RA treatment alters the risk of sinus disease. Methods. As part of a longitudinal study of rheumatic disease outcomes, 7,243 patients with RA, 1,667 with osteoarthritis (OA), and 447 with fibromyalgia (FM) were evaluated for important sinus problems in 2003. We defined an important sinus problem as one that required a physician visit. Results. The lifetime prevalence of sinus disorders among all patients was 42.9%. During the previous 6 months 22.3% of patients with RA, 23.9% with OA, and 25.1% with FM visited a physician for a sinus problem and 22.4%, 23.9%, and 25.1% , respectively, received a prescription medication for a sinus problem. After adjustment for age and sex, the rate of physician visits for a sinus problem was significantly lower for patients with RA (22.1%) compared to patients with OA (24.8%). The strongest predictor of sinus problems among all patients was a history of allergy or asthma. Sinus problems were more common among users of etanercept: odds ratio (OR) 1.2; 95% confidence interval (CI): 1.0-1.4 univariably, and OR 1.2; 95% CI: 1.0-1.4 multivariably. Sulfasalazine (OR 0.7; 95% CI: 0.5-0.9) and leflunomide (OR 0.8; 95% CI: 0.7-1.0) had a protective effect on sinus problems. Conclusions. Sinus problems are decreased in patients with RA compared to OA and FM. Slight protective effects on sinus problems are noted with sulfasalazine and leflunomide, and a slight increase in risk of sinus problems is noted with etanercept.

Original languageEnglish (US)
Pages (from-to)2412-2415
Number of pages4
JournalJournal of Rheumatology
Volume33
Issue number12
StatePublished - Dec 1 2006

Fingerprint

Rheumatoid Arthritis
leflunomide
Osteoarthritis
Fibromyalgia
Odds Ratio
Confidence Intervals
Sulfasalazine
Therapeutics
Physicians
Rheumatic Diseases
Prescriptions
Longitudinal Studies
Hypersensitivity
Asthma

Keywords

  • Anti-tumor necrosis factor therapy
  • Leflunomide
  • Rheumatoid arthritis
  • Sinusitis
  • Sulfasalazine

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

The association of rheumatoid arthritis and its treatment with sinus disease. / Michaud, Kaleb; Wolfe, Frederick.

In: Journal of Rheumatology, Vol. 33, No. 12, 01.12.2006, p. 2412-2415.

Research output: Contribution to journalArticle

@article{ffe78f2123ee4cd7a83b3ab841228f9e,
title = "The association of rheumatoid arthritis and its treatment with sinus disease",
abstract = "Objective. To determine if rates of sinus disease are increased in patients with rheumatoid arthritis (RA) and whether RA treatment alters the risk of sinus disease. Methods. As part of a longitudinal study of rheumatic disease outcomes, 7,243 patients with RA, 1,667 with osteoarthritis (OA), and 447 with fibromyalgia (FM) were evaluated for important sinus problems in 2003. We defined an important sinus problem as one that required a physician visit. Results. The lifetime prevalence of sinus disorders among all patients was 42.9{\%}. During the previous 6 months 22.3{\%} of patients with RA, 23.9{\%} with OA, and 25.1{\%} with FM visited a physician for a sinus problem and 22.4{\%}, 23.9{\%}, and 25.1{\%} , respectively, received a prescription medication for a sinus problem. After adjustment for age and sex, the rate of physician visits for a sinus problem was significantly lower for patients with RA (22.1{\%}) compared to patients with OA (24.8{\%}). The strongest predictor of sinus problems among all patients was a history of allergy or asthma. Sinus problems were more common among users of etanercept: odds ratio (OR) 1.2; 95{\%} confidence interval (CI): 1.0-1.4 univariably, and OR 1.2; 95{\%} CI: 1.0-1.4 multivariably. Sulfasalazine (OR 0.7; 95{\%} CI: 0.5-0.9) and leflunomide (OR 0.8; 95{\%} CI: 0.7-1.0) had a protective effect on sinus problems. Conclusions. Sinus problems are decreased in patients with RA compared to OA and FM. Slight protective effects on sinus problems are noted with sulfasalazine and leflunomide, and a slight increase in risk of sinus problems is noted with etanercept.",
keywords = "Anti-tumor necrosis factor therapy, Leflunomide, Rheumatoid arthritis, Sinusitis, Sulfasalazine",
author = "Kaleb Michaud and Frederick Wolfe",
year = "2006",
month = "12",
day = "1",
language = "English (US)",
volume = "33",
pages = "2412--2415",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "12",

}

TY - JOUR

T1 - The association of rheumatoid arthritis and its treatment with sinus disease

AU - Michaud, Kaleb

AU - Wolfe, Frederick

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Objective. To determine if rates of sinus disease are increased in patients with rheumatoid arthritis (RA) and whether RA treatment alters the risk of sinus disease. Methods. As part of a longitudinal study of rheumatic disease outcomes, 7,243 patients with RA, 1,667 with osteoarthritis (OA), and 447 with fibromyalgia (FM) were evaluated for important sinus problems in 2003. We defined an important sinus problem as one that required a physician visit. Results. The lifetime prevalence of sinus disorders among all patients was 42.9%. During the previous 6 months 22.3% of patients with RA, 23.9% with OA, and 25.1% with FM visited a physician for a sinus problem and 22.4%, 23.9%, and 25.1% , respectively, received a prescription medication for a sinus problem. After adjustment for age and sex, the rate of physician visits for a sinus problem was significantly lower for patients with RA (22.1%) compared to patients with OA (24.8%). The strongest predictor of sinus problems among all patients was a history of allergy or asthma. Sinus problems were more common among users of etanercept: odds ratio (OR) 1.2; 95% confidence interval (CI): 1.0-1.4 univariably, and OR 1.2; 95% CI: 1.0-1.4 multivariably. Sulfasalazine (OR 0.7; 95% CI: 0.5-0.9) and leflunomide (OR 0.8; 95% CI: 0.7-1.0) had a protective effect on sinus problems. Conclusions. Sinus problems are decreased in patients with RA compared to OA and FM. Slight protective effects on sinus problems are noted with sulfasalazine and leflunomide, and a slight increase in risk of sinus problems is noted with etanercept.

AB - Objective. To determine if rates of sinus disease are increased in patients with rheumatoid arthritis (RA) and whether RA treatment alters the risk of sinus disease. Methods. As part of a longitudinal study of rheumatic disease outcomes, 7,243 patients with RA, 1,667 with osteoarthritis (OA), and 447 with fibromyalgia (FM) were evaluated for important sinus problems in 2003. We defined an important sinus problem as one that required a physician visit. Results. The lifetime prevalence of sinus disorders among all patients was 42.9%. During the previous 6 months 22.3% of patients with RA, 23.9% with OA, and 25.1% with FM visited a physician for a sinus problem and 22.4%, 23.9%, and 25.1% , respectively, received a prescription medication for a sinus problem. After adjustment for age and sex, the rate of physician visits for a sinus problem was significantly lower for patients with RA (22.1%) compared to patients with OA (24.8%). The strongest predictor of sinus problems among all patients was a history of allergy or asthma. Sinus problems were more common among users of etanercept: odds ratio (OR) 1.2; 95% confidence interval (CI): 1.0-1.4 univariably, and OR 1.2; 95% CI: 1.0-1.4 multivariably. Sulfasalazine (OR 0.7; 95% CI: 0.5-0.9) and leflunomide (OR 0.8; 95% CI: 0.7-1.0) had a protective effect on sinus problems. Conclusions. Sinus problems are decreased in patients with RA compared to OA and FM. Slight protective effects on sinus problems are noted with sulfasalazine and leflunomide, and a slight increase in risk of sinus problems is noted with etanercept.

KW - Anti-tumor necrosis factor therapy

KW - Leflunomide

KW - Rheumatoid arthritis

KW - Sinusitis

KW - Sulfasalazine

UR - http://www.scopus.com/inward/record.url?scp=33846109927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846109927&partnerID=8YFLogxK

M3 - Article

C2 - 17143978

AN - SCOPUS:33846109927

VL - 33

SP - 2412

EP - 2415

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 12

ER -